SABR for renal cell carcinoma offers excellent outcomes

Stereotactic ablative radiotherapy (SABR) for patients with primary renal cell carcinoma is well tolerated and is associated with excellent local oncologic control, researchers concluded based on a pooled analysis of data from patients treated with the modality at 9 institutions in 5 countries.
Renal and Urology News